Author: Ravi Shankar

Collaboration builds on Itron’s proven security-first platform and integrates Crytica’s Rapid Detection, Alert and Isolation technology to help utilities prepare for emerging cyber and operational risks at the grid edge

LIBERTY LAKE, Wash., Sept. 22, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), the intelligent infrastructure provider for modern energy and water management, and Crytica Security announced a strategic technology collaboration to advance rapid cyber threat detection and operational visibility across its intelligent grid-edge infrastructure.

Cybersecurity threats to critical infrastructure are ever-present and evolving rapidly. As utilities modernize their infrastructure, deploy more distributed intelligence at the grid edge, integrate distributed energy resources and prepare for new AI-enabled threat vectors, security must adapt. Utilities require solutions that build on proven protection while adapting faster to new risks emerging across distributed, connected and intelligent networks.

The collaboration is designed to integrate Crytica’s patented Rapid Detection, Alert and Isolation technology, RDAi™, into Itron’s Grid Edge Intelligence portfolio, adding continuous integrity monitoring and actionable alerts closer to where grid activity occurs. The combination of Itron’s secure, utility-grade platform with Crytica’s deterministic detection technology, provides utilities with an additional layer of cybersecurity visibility across IT and OT environments and intelligent grid edge devices, meter-hosted applications and edge workloads as the security landscape evolves.

Itron’s Grid Edge Intelligence portfolio is built on a strong security foundation that includes layered device, network, communications and data protection. The integration of Crytica’s RDAi technology is intended to extend that foundation with active, embedded monitoring that can detect unauthorized changes to devices without negatively affecting device performance. This added layer helps utilities identify potential compromise earlier, accelerate investigation and response, and strengthen resilience across critical field assets.

“Utilities are moving intelligence closer to the edge of the grid, and cybersecurity must move with it,” said Don Reeves, Itron’s senior vice president of Outcomes. “Itron has long helped utilities deploy secure, reliable and resilient infrastructure at scale. Our collaboration with Crytica builds on that foundation by adding rapid, embedded threat detection designed for the next generation of grid-edge applications. Together, we are helping utilities prepare for what is coming next while continuing to protect the essential services communities rely on every day.”

Unlike traditional cybersecurity approaches that focus primarily on centralized systems or enterprise endpoints, the Itron-Crytica collaboration is designed to bring monitoring directly into resource-constrained utility field devices and the applications running on them. Crytica’s lightweight probe continuously monitors and delivers high-fidelity alerts when unauthorized changes are detected. This approach is designed to complement existing cybersecurity platforms by extending visibility into operational technology environments where traditional endpoint tools may not operate.

This collaboration aims to advance embedded grid-edge threat detection by helping utilities monitor both the meter and meter-hosted applications through a common integrity monitoring framework, a capability not available to utilities today.

The collaboration also supports broader operational awareness. In addition to cybersecurity monitoring, the integration is expected to provide performance-related alerts that help utilities identify conditions that may affect device health, reliability and availability. These capabilities can help utilities improve situational awareness, prioritize investigation and support more resilient operations as AMI networks evolve into intelligent grid-edge platforms.

“Crytica’s RDAi technology was purpose-built for demanding, resource-constrained operational environments,” said C. Lloyd Mahaffey, Executive Chairman and Co-Founder, Crytica Security. “By working with Itron, we can extend rapid detection and actionable alerts into utility grid-edge infrastructure at scale, helping utilities see potential issues earlier and respond with greater confidence.”

The collaboration reinforces Itron’s strategy to help utilities transition from traditional AMI to Grid Edge Intelligence by combining distributed intelligence, intelligent connectivity, advanced analytics and security-centered innovation. As utilities prepare for more dynamic grid operations, the ability to detect, alert and respond closer to the edge will become increasingly important to maintaining reliability, resilience and trust.

Customer benefits

• Builds on a proven security foundation: Extends Itron’s secure, utility-grade platform with an additional layer of embedded threat detection.
• Strengthens grid-edge visibility: Helps utilities monitor intelligent devices, meter-hosted applications and edge workloads closer to where grid activity occurs.
• Enables faster detection and response: Uses Crytica’s RDAi technology to identify unauthorized instruction-set changes within seconds and generate actionable alerts.
• Supports operational resilience: Adds visibility into device health and performance conditions that may affect reliability, availability or service delivery.
• Prepares utilities for emerging threats: Helps utilities adapt to an evolving threat landscape, including risks associated with increasing connectivity, distributed intelligence and AI-enabled cyber activity.

About Itron
Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: www.itron.com

About Crytica Security
Crytica Security’s patented Rapid Detection, Alert (RDAi™), and Isolation technology embeds a lightweight, under 100 Kilobyte, Probe directly within operational technology, IoT, embedded systems and other cyber-physical environments to continuously monitor system integrity and detect unauthorized changes to instruction sets within seconds. Designed to complement existing cybersecurity platforms, RDAi extends visibility into devices where traditional tools may not operate, delivering deterministic detection and actionable alerts that enable faster security response for mission-critical operations. See how RDAi can help you “detect and protect” by visiting www.cryticasecurity.com.

Media Contacts:
Itron, Inc.
Alison Mallahan
Senior Manager, Corporate Communications
509-891-3802
PR@Itron.com

Paul Vincent
Vice President, Investor Relations
512-560-1172
Investors@itron.com

Crytica Security, Inc.
Jake Blanchard, VP, OEM Sales
Email: jake@cryticasecurity.com
Mobile: (208) 559-3399

MINNEAPOLIS, Sept. 22, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us,” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a strategic partnership with Atropos Health, the creator of real-world evidence for clinical decision-making under a multi-year agreement. The partnership adds OneMedNet’s regulatory decision-grade data to Atropos’ platform and customer offerings under a fee arrangement adding to our Annual Recurring Revenue (ARR).

The partnership embeds OneMedNet’s data directly into Atropos Health’s evidence-generation platform, giving Atropos customers access to more multi-modal data drawn from our network of over 90 million patient journeys. Our multi-modal RWD brings clinical depth that elevates evidence quality well beyond what claims or Electronic Health Record (EHR) datasets alone can deliver, positioning our RWD as differentiated, high-value data within the partnership.

Under the partnership, Atropos’ customers – health systems, life sciences organizations, and researchers – will be able to purchase additional OneMedNet multi-modal data from OneMedNet through the Atropos platform. The collaboration is structured as a 3-year subscription-based license purchased by Atropos, providing seamless, ongoing data access and data delivery.

Solving the Evidence Gap Together

Most Real-World Evidence today lacks the clinical richness of imaging and multimodal data. Atropos Health solves for speed and rigor by adding imaging to its tools, providing more real-world evidence than any other platform. OneMedNet supplies the regulatory-grade depth and breadth both companies believe is essential for truly credible, decision-grade evidence. The subscription partnership unites these strengths, making OneMedNet’s differentiated data a core, recurring component of Atropos’ platform workflows.

“This partnership perfectly exemplifies our strategy: transforming our unique, Direct-from-Source, regulatory decision-grade data into long-term subscription collaborations that put our data directly into our partners’ hands removing the friction that has traditionally slowed access to high-quality Real-World Data,” said Aaron Green, President & CEO of OneMedNet. “Atropos sets the standard for rapid, personalized evidence, and we strengthen the foundational data beneath it so their customers can move from question to evidence without the usual barriers.”

“High-quality evidence starts with fit-for-purpose data, and multimodal depth is now table stakes,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Our partnership with OneMedNet brings regulatory-grade imaging and multimodal richness into our platform, enabling richer insights for our clients as we work together to close the evidence gap.”

The collaboration reflects surging demand for our multimodal, regulatory-grade RWD and further validates OneMedNet’s focus on converting differentiated data assets into long-term, partnership-driven value.

About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training. Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, the benefits of the Atropos Health partnership, statements regarding demand for our products and services, the composition and durability of our customer base, the speed of order fulfillment, the acceptance of our delivered data sets allowing for the conversion of bookings to revenue, our ability to achieve our operational strategies, our expected growth in the business, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease

First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028

Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity

Denver, CO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn’s disease (CD).

“FDA clearance of the ASCENTRA-CD IND marks another significant milestone for PALI-2108 and meaningfully expands our Phase 2 development program across inflammatory bowel disease,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “Crohn’s disease remains a progressive condition where many patients experience inadequate response or loss of response to existing therapies. We believe PALI-2108’s differentiated prodrug design, once-daily oral dosing and targeted activation within the ileum and colon provide a compelling foundation for development in this population. Importantly, we enter Phase 2 with direct clinical experience demonstrating favorable tolerability, targeted tissue exposure, PDE4 target engagement and encouraging early biological and endoscopic activity.”

ASCENTRA-CD Phase 2 Trial Design

ASCENTRA-CD is a multicenter, open-label, single-arm Phase 2 study designed to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of PALI-2108 in approximately 60 adults with moderate to severe Crohn’s disease. Patients will undergo a 14-day dose titration to the target dose of PALI-2108 30 mg orally once daily. The study includes a 12-week induction phase followed by a 36-week maintenance phase.

The primary endpoint is endoscopic response at Week 12, defined as at least a 50% reduction from baseline in the Simple Endoscopic Score for Crohn’s Disease (SES-CD), based on blinded central endoscopic review. Key secondary endpoints at Week 12 include clinical remission, endoscopic remission, PRO-2 remission (a patient-reported outcome of abdominal pain and stool frequency), clinical response and combined clinical remission and endoscopic response, with additional maintenance assessments through Week 48.

The Company anticipates first patient dosing in Q1 2027, and a primary efficacy readout in Q1 2028.

PALI-2108 in Crohn’s Disease

Crohn’s disease is a chronic, progressive inflammatory condition in which persistent or recurrent inflammation can lead to irreversible tissue remodeling, fibrosis and bowel disability.

PALI-2108 is designed to address these challenges through an oral, locally activated prodrug approach. Following oral administration, the drug is activated in the terminal ileum and colon, generating high local intestinal exposure while also supporting sustained systemic exposure and a differentiated pharmacokinetic profile. PALI-2108 has already been evaluated in patients with fibrostenotic Crohn’s disease, providing direct clinical experience with ileal and colonic tissue exposure, PDE4 target engagement and endoscopic activity. ASCENTRA-CD is designed to extend those findings into a broader moderate to severe Crohn’s disease population using centrally read endoscopic response at Week 12 as the primary endpoint.

With Phase 2 development now advancing in both ulcerative colitis and Crohn’s disease, Palisade is advancing a broad clinical development program for PALI-2108 across the two major forms of inflammatory bowel disease. Together, ASCENTRA-UC in ulcerative colitis and ASCENTRA-CD in Crohn’s disease are designed to generate a broader clinical dataset around the efficacy, safety and pharmacology of PALI-2108.

About PALI-2108

PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon. Across Phase 1 studies in healthy volunteers and patients with ulcerative colitis and fibrostenotic Crohn’s disease, PALI-2108 demonstrated favorable safety and tolerability, differentiated pharmacokinetics and sustained PDE4 inhibition above IC90, supporting advancement into Phase 2 development.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases.

The Company’s lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD do not achieve durable remission, lose response over time, or discontinue treatment because of safety or tolerability limitations. The Company believes PALI-2108 has the potential to address these limitations through once-daily oral dosing, targeted lower-intestinal bioactivation and broad PDE4-mediated anti-inflammatory activity.

For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

Attachment

• Palisade Bio, Inc.

First patient marks Polyrizon’s transition into a clinical-stage company.

The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis

Raanana, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical- stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the enrollment of the first patient in its U.S. clinical study to evaluate NASARIX (PL-14), the Company’s investigational Allergy Blocker, in patients with seasonal allergic rhinitis (SAR).

The enrollment of the first patient represents a significant milestone for Polyrizon and marks the Company’s transition into the clinical stage of development.

“This is a defining milestone for Polyrizon,” said Tomer Izraeli, Chief Executive Officer of Polyrizon. “The enrollment of the first patient in our U.S. study represents the culmination of extensive product development, preclinical evaluation, manufacturing and regulatory preparation, and moves NASARIX into clinical evaluation in patients for the first time. We believe this study represents an important step toward our goal of developing a differentiated, drug-free approach for people suffering from seasonal allergies.”

NASARIX is a non-pharmacological, drug-free, mucoadhesive hydrogel nasal spray designed to form a physical barrier within the nasal cavity. The barrier is intended to reduce contact between inhaled airborne allergens and the nasal mucosa, thereby helping alleviate symptoms associated with allergic rhinitis.

The prospective, multicenter, randomized, single-blind, two-arm study is expected to randomize 120 patients at 5 clinical sites in the United States. Participants will be randomized 1:1 to receive either NASARIX Allergy Blocker or a saline nasal spray comparator.

The study is designed to evaluate the efficacy, safety and tolerability of NASARIX in adults with seasonal allergic rhinitis. The primary efficacy endpoint will assess the difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between PL-14 and the saline comparator over the first 14 treatment days. Safety assessments will include the frequency and severity of treatment-emergent adverse events as well as assessments of local and overall tolerability.

“Moving the NASARIX Allergy Blocker into a first-in-human clinical study is an important step in the development of our Capture and Contain™ technology from concept through product development and preclinical evaluation,” said Dr. Tidhar Turgeman, Chief Technology Officer of Polyrizon. “The study has been designed to generate data regarding efficacy and safety under real-world seasonal allergen exposure. We look forward to advancing enrollment across our U.S. clinical sites and evaluating NASARIX’s potential as a drug-free option for patients with seasonal allergic rhinitis.”

About NASARIX^TM

NASARIX^TM is Polyrizon’s proprietary nasal spray designed to create a protective barrier within the nasal cavity, helping to prevent contact between inhaled allergens and the nasal mucosa. The product is being developed as a non-drug approach for the management of seasonal allergic rhinitis.

About Polyrizon

Polyrizon is a clinical- stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon is further developing certain aspects of its C&C hydrogel technology, such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected conduct, timing and progress of the NASARIX (PL-14) clinical study, including patient enrollment, the anticipated number of patients and clinical sites, the study’s evaluation of efficacy, safety and tolerability, the generation of clinical data, and NASARIX’s potential as a drug-free option for patients with seasonal allergic rhinitis. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

Expands Access to Comprehensive Firefighter PPE Care with the Opening of its Colorado Facility

New Facility Provides Fire Departments with Cleaning, Inspection, Repair, Rental PPE, NFPA 1850 Training and Department Cleaning Equipment Under One Roof

HUNTSVILLE, Ala., Sept. 22, 2026 (GLOBE NEWSWIRE) — Lakeland Industries, Inc. (“Lakeland Fire + Safety” or “Lakeland”) (NASDAQ: LAKE) announced today the expansion of its network of independent service providers for comprehensive firefighter PPE care with the opening of its new Centennial, Colorado facility, Colorado PPE. Colorado PPE combines responsive department-focused service with the resources and capabilities of Lakeland Fire + Safety to deliver comprehensive PPE care, rental and training solutions.

Colorado PPE operates as an independent service provider, offering fire departments a more personal approach while bringing the resources and capabilities of a larger organization to the relationship. The facility represents a broader approach to firefighter PPE management—one that goes beyond compliance to focus on the people who rely on their gear every time they answer a call.

“We believe in maintaining a higher level of service for our fire departments,” said Mike Glaze, President of California PPE. “Our goal is to ensure our firefighters and departments are valued and their gear is in the best condition it can be in to protect them when it leaves our facility and enters their service.”

NFPA 1850, is the National Fire Protection Association standard that establishes requirements for the selection, care, maintenance, inspection, cleaning, repair, retirement, and management of protective ensembles and clothing used by firefighters and emergency responders. Under this standard, it establishes a minimum performance benchmark of removing 50% of heavy metals, polycyclic aromatic hydrocarbons (PAHs), and volatile organic compounds (VOCs) from contaminated PPE. Based on test results from UL, a third-party testing agency, our cleaning process achieved average cleaning efficiencies of 88% removal of VOCs and 89% removal of heavy metals—exceeding the minimum benchmark and raising the bar for PPE cleaning in the industry.

The new facility provides comprehensive PPE services designed to support firefighters throughout the lifecycle of their gear, including cleaning, inspection and repair. Rental PPE is also available to help departments maintain readiness when gear is temporarily out of service or when additional equipment is needed for training and other operational requirements. Colorado PPE will also provide NFPA 1850 training and station cleaning equipment such as extractors to help departments better understand and implement effective PPE care programs.

“Every department has different needs, different resources and different challenges. Our job is to understand those needs and help build a PPE care program that works for them,” said Misty Johnson, Operations Manager at Colorado PPE. “We clean, inspect and repair PPE with purpose—going beyond the minimum to help protect those who protect us because when it comes to protecting firefighters, meeting the minimum should be the starting point, not the finish line.”

Jim Jenkins, President and Chief Executive Officer of Lakeland, added, “Colorado PPE is committed to helping departments care for their gear with purpose and looks forward to serving the Colorado fire community. PPE care is ultimately about more than equipment, standards or processes. It is about the people wearing the gear. The firefighters who run toward emergencies trust their PPE to provide protection in some of the most demanding environments imaginable and Colorado PPE believes the care that gear receives should reflect the importance of that responsibility.”

About Lakeland Fire + Safety

Lakeland Fire + Safety manufactures and sells a comprehensive line of fire services and industrial protective clothing and accessories for the industrial and first responder markets. In addition, we provide decontamination, repair and rental services that complement our fire services portfolio. Our products are sold globally by our in-house sales teams, our customer service group, and authorized independent sales representatives to a strategic global network of selective fire and industrial distributors and wholesale partners. Our authorized distributors supply end users across various industries, including integrated oil, chemical/petrochemical, automobile, transportation, steel, glass, construction, smelting, cleanroom, janitorial, pharmaceutical, and high-tech electronics manufacturers, as well as scientific, medical laboratories, and the utilities industry. In addition, we supply federal, state and local governmental agencies and departments, including fire and law enforcement, airport crash rescue units, the Department of Defense, the Department of Homeland Security and the Centers for Disease Control. Internationally, we sell to a mix of end-users directly and to industrial distributors, depending on the particular country and market. In addition to the United States, sales are made into more than 50 foreign countries, the majority of which were into China, the European Economic Community (“EEC”), Canada, Chile, Argentina, Commonwealth of Independent States (“CIS”) Region, Colombia, Mexico, Ecuador, India, Uruguay, Middle East, Southeast Asia, Australia, Hong Kong and New Zealand.

For more information about Lakeland, please visit the Company’s website at www.lakeland.com.

About Colorado PPE

Located in Centennial, Colorado, Colorado PPE provides comprehensive PPE care and resources for fire departments, including cleaning, inspection, repair, rental PPE, NFPA 1850 training and equipment, and advanced decontamination solutions.

Colorado PPE combines the responsive, department-focused approach of an independent service provider with the resources, technical expertise and broader capabilities of Lakeland Fire + Safety. This combination allows Colorado PPE to deliver personal service at the local level while continuing to invest in technologies and capabilities designed to improve firefighter safety and PPE care. For more information visit https://coloradoppe.com/.

Colorado PPE
6675 S. Kenton St., Suite 113
Centennial, CO 80111

Hours: Monday–Friday, 8:00 a.m.-3:30 p.m. MT
Email: customerservice@coloradoppe.com

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains estimates, predictions, opinions, goals and other “forward-looking statements” as that phrase is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, references to the Company’s predictions or expectations of future business or financial performance as well as its goals and objectives for future operations, financial and business trends, business prospects, and management’s expectations for earnings, revenues, expenses, inventory levels, capital levels, liquidity levels, or other future financial or business performance, strategies or expectations, including without limitation our plans to deliver comprehensive care, rental and training solutions. All statements, other than statements of historical facts, which address Lakeland’s expectations of sources or uses for capital, or which express the Company’s expectation for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Forward-looking statements involve risks, uncertainties and assumptions as described from time to time in press releases and Forms 8-K, registration statements, quarterly and annual reports and other reports and filings filed with the Securities and Exchange Commission or made by management. As a result, there can be no assurance that Lakeland’s future results will not be materially different from those described herein as “believed,” “projected,” “planned,” “intended,” “anticipated,” “can,” “estimated” or “expected,” or other words which reflect the current view of the Company with respect to future events. We caution readers that these forward-looking statements speak only as of the date hereof. The Company hereby expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which such statement is based, except as may be required by law.

Investor Relations
Chris Tyson
Executive Vice President
MZ Group – MZ North America
949-491-8235
LAKE@mzgroup.us 
www.mzgroup.us

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/1466df9b-0c9b-4b3c-a9ff-e4d7ba3b6eeb

https://www.globenewswire.com/NewsRoom/AttachmentNg/9ea55120-6143-4807-9908-cd5baf7bf773

https://www.globenewswire.com/NewsRoom/AttachmentNg/ae36e0fd-d833-4128-9654-cf7c4f179bac

https://www.globenewswire.com/NewsRoom/AttachmentNg/225c9d58-004e-40c7-b0fb-b9c41d3d91d6

https://www.globenewswire.com/NewsRoom/AttachmentNg/1eddf22f-adef-42a4-b74e-81a0a27d0cb3

https://www.globenewswire.com/NewsRoom/AttachmentNg/156dd466-2fdd-4937-b313-66a65fa7ec75

https://www.globenewswire.com/NewsRoom/AttachmentNg/913d3647-aadc-41cb-923b-ff7c5e36cb7a 

Approved Exploration Plan of Operations and 2026 Annual Operating Plan Clear the Way for Drilling; Company Targeting Up to 15,000 Feet of Additional Diamond Core Drilling This Season

BOISE, Idaho, Sept. 22, 2026 (GLOBE NEWSWIRE) — Idaho Copper Corporation (NYSE American: COPR) (“Idaho Copper” or the “Company”), a critical minerals developer advancing the flagship CuMo copper-molybdenum-silver project in Idaho, today announced that the U.S. Forest Service, Boise National Forest (“USFS”) sent a letter approving the Company’s Exploration Plan of Operations (“PoO”) and its 2026 annual operating plan for exploration at the CuMo project in Boise County, Idaho, clearing the way for drilling and roadbuilding and maintenance activities to commence.

On September 9, 2026, the USFS accepted the Company’s signed Forest Service Evaluation form and incorporated all required changes, modifications and mitigations into the approved PoO, and has accepted the Company’s reclamation surety bond. The letter further notes that the Company has provided documentation showing that all other permits necessary for the project are in place and in good standing. The USFS also approved the Company’s 2026 annual operating plan, which was reviewed and field verified by agency staff. The approved PoO is effective for six years from the first day of operations, inclusive of final reclamation.

The approval follows the Decision Notice and Finding of No Significant Impact issued by the USFS on March 14, 2025 under an Environmental Assessment, which completed the federal environmental review of the CuMo exploration plan. The September 9 letter satisfies the remaining administrative conditions to that decision and authorizes the Company to begin work.

Management Commentary

“Approval of our Exploration Plan of Operations and our 2026 annual operating plan is the culmination of a decade of work with the Forest Service, and it is the milestone that should turn CuMo from a concept into an active drill program,” said Andrew Brodkey, Chief Executive Officer of Idaho Copper. “We have an approved plan, an accepted reclamation bond, and the other permits this project requires. In a country where federal permitting is often the single largest obstacle impeding advancement of a critical minerals deposit, that is a meaningful achievement.”

“Our priority for the balance of this season is infill drilling that tightens confidence in the existing deposit, and we plan to carry that work into a substantially larger campaign in 2027 aimed at completing the drilling needed for a Prefeasibility Study. Every foot we drill from here will be directed at advancing CuMo toward a development decision, and at doing so under the environmental commitments we have made to the Forest Service and to the communities around this project,” concluded Brodkey.

About Idaho Copper Corporation

Idaho Copper Corporation (NYSE American: COPR) is a critical minerals developer focused on exploring and developing the CuMo copper-molybdenum-silver-tungsten-rhenium project located in Boise County, Idaho. The CuMo project is one of the largest undeveloped copper deposits in the U.S., which management believes is among the largest undeveloped primary molybdenum deposits in the world, which also contains significant amounts of silver, rhenium, and tungsten — all considered critical or of strategic importance. The project comprises approximately 2,640 acres and consists of 126 federal unpatented lode mining claims and 6 patented mining claims. To learn more, please visit www.idaho-copper.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include statements regarding the Company’s 2026 and 2027 exploration and drilling programs, the expected footage, scope and timing thereof, and the planned Prefeasibility Study and the anticipated timing thereof. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made, including risks related to metal price volatility, mining and processing performance, drill rig and contractor availability, weather and the length of the permitted operating season, permitting, and the availability of financing for and development of the CuMo project. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements are discussed or identified in our filings with the Securities and Exchange Commission (the “SEC”), including the risk factors contained in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and registration statements. In addition, this press release contains time-sensitive information that reflects management’s best analysis only as of the date of this press release. Idaho Copper does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(262) 357-2918
COPR@mzgroup.us
www.mzgroup.us

Management to Participate in Gabelli Funds’ 4th Annual PFAS Symposium and Noble Capital Markets’ October 2026 Emerging Growth Virtual Equity Conference

CORSICANA, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that management will participate in two upcoming investor conferences: Gabelli Funds’ 4th Annual PFAS Symposium and Noble Capital Markets’ October 2026 Emerging Growth Virtual Equity Conference.

Richard MacPherson, President and CEO of Birchtech, is scheduled to deliver a corporate presentation at each event and will host one-on-one meetings with institutional investors at the Noble Capital Markets conference, as follows:

Gabelli Funds’ 4th Annual PFAS Symposium
Conference Date: September 24, 2026
Location: Convene, 530 Fifth Avenue, New York, NY
Format: Presentation Only
Presentation Time: 2:30 PM Eastern Time
Webcast: https://gabelli.com/event/4th-annual-pfas-symposium/

Noble Capital Markets’ October 2026 Emerging Growth Virtual Equity Conference
Conference Dates: October 1-2, 2026
Location: Virtual
Format: Presentation & 1×1 Meetings
Presentation Date: October 2, 2026
Presentation Time: 1:00 PM Eastern Time
Webcast: https://channelchek.cc/3TmsB7g

A live audio webcast and archive of each presentation will be available using the webcast links above. Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at BCHT@mzgroup.us.

About Birchtech Corp.

Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) is a leader in specialty activated carbon technologies delivering innovative solutions for air and water purification to support a cleaner, more sustainable future. The Company provides patented SEA^® sorbent technologies for mercury emissions capture for the coal-fired utility sector and SEA disruptive water purification technologies with a specialization on removing contaminants, including ‘forever chemicals’ such as PFAS, from potable water and industrial wastewater. Backed by a strong intellectual property portfolio and a team of activated carbon experts, Birchtech provides cleaner air to North American communities and is applying this expertise to a novel approach in water purification. To learn more, please visit www.birchtech.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include statements relating to expected developments and growth in Birchtech’s business, as well as anticipated investor engagements and the Company’s participation in investor conferences. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. Birchtech does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance or other forward-looking statements contained in this release can be found in Birchtech’s periodic filings with the Securities and Exchange Commission or Canadian securities regulators.

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
BCHT@mzgroup.us
www.mzgroup.us

This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement.

Disclosure: This does not represent material news, partnerships or investment advice.

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — via AINewsWire — MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX) today announces its placement in an editorial published by AINewsWire (AINW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “What If the Next Generation of AI Data Centers Goes to the Energy Source?”, please visit: https://ibn.fm/awVTg

Artificial intelligence may be transforming what computers can do, but the next phase of that revolution increasingly depends on something far more fundamental: electricity. As AI data centers grow larger and more power intensive, governments and technology companies are confronting a question that could reshape both the energy and digital-infrastructure industries: What if, instead of continually moving energy to data centers, the next generation of data centers is built where abundant primary energy already exists?

That possibility is particularly relevant to MAX Power Mining Corp., a leading North American public company focused on the emerging natural hydrogen sector. MAX Power is advancing Canada’s first confirmed subsurface natural hydrogen system at the Lawson Discovery in south-central Saskatchewan, where the company is moving rapidly through a multi-well commercial validation program.

About MAX Power Mining Corp.

MAX Power is an innovative mineral and energy exploration company focused on the shift to decarbonization. The company’s Lawson Discovery near Central Butte, Saskatchewan, represents Canada’s first-ever subsurface natural hydrogen system confirmed through deep drilling with data validated by three independent labs. MAX Power has built dominant district-scale land positions across Saskatchewan with approximately 1.3 million acres (521,000 hectares) of permits covering prime exploration ground prospective for large-volume accumulations of natural hydrogen. MAX Power also holds a portfolio of properties in the United States and Canada focused on critical minerals. These properties are highlighted by a 2024 diamond drilling discovery at the Willcox Playa Lithium Project in southeast Arizona, 100%-owned by MAX Power’s U.S. subsidiary. MAX Power is committed to responsible exploration and development practices that prioritize environmental stewardship, meaningful community engagement and strong corporate governance.

For further information, please visit the company’s website at www.MAXPowerMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MAXXF are available in the company’s newsroom at https://ibn.fm/MAXXF

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or republished: https://www.AINewsWire.com/Disclaimer

AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com

AINewsWire is powered by IBN

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — via AINewsWire — Nightfood Holdings Inc. (OTCQB: NGTF) today announces its placement in an editorial published by AINewsWire (“AINW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Wafer Inspection Market Set to Approach $10 Billion by 2030,” please visit: https://ibn.fm/FpZPM

The artificial intelligence boom has moved its toughest bottleneck. It is no longer just about who can etch the smallest transistor. Increasingly, it is about who can package finished chips fast enough, cleanly enough and in high enough volume to keep AI data centers supplied. NVIDIA CEO Jensen Huang has said publicly that the company is expanding capacity for CoWoS-L, the advanced packaging process behind its newest chips, while continuing to push suppliers on yield and production speed.

That same pressure is now rippling through the automation and inspection layer that supports packaging lines, an area where Nightfood Holdings Inc. (OTCQB: NGTF), doing business as TechForce Robotics, intends to compete. Last week, the company announced the formation of TechForce Advanced Manufacturing Inc., a majority-owned subsidiary built with a Taiwan-based manufacturing partner to expand production of automated Wafer Sorter and AOI systems for 8-inch and 12-inch wafers, with initial production and revenue targeted for the fourth quarter of 2026. 

About Nightfood Holdings Inc. (dba TechForce Robotics)

Nightfood Holdings Inc., doing business as TechForce Robotics, is an advanced robotics and automation company focused on delivering intelligent, scalable solutions for industrial and commercial applications. The company integrates robotics, artificial intelligence and software-driven systems to optimize operations, improve efficiency and enable next-generation automation. TechForce Robotics partners with organizations to design and deploy customized robotic solutions that address evolving operational requirements.

About TechForce Advanced Manufacturing
TechForce Advanced Manufacturing Inc. is a Nevada corporation formed to develop, manufacture, commercialize, install and support semiconductor automation and inspection systems. Its initial focus is expanding Wafer Sorter and AOI production for wafer-based semiconductor and CoWoS-related advanced-packaging applications, while pursuing future applications supporting emerging Chip-on-Panel-on-Substrate (“CoPoS”) manufacturing process.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

For more information, visit Nightfood Holdings.

About AINewsWire

AINewsWire (AINW) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

DISCLAIMER: AINewsWire (AINW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by AINW are solely those of AINW. Readers of this Article and content agree that they cannot and will not seek to hold liable AINW for any investment decisions by their readers or subscribers. AINW is a news dissemination and financial marketing solutions provider and NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, AINW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

AINW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,”, “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AINW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: 
https://www.AINewsWire.com/Disclaimer

AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com

AINewsWire is powered by IBN

Not for distribution to U.S. newswire services or for dissemination in the United States.

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — (TSX: PGIC; PGIC.PR.A) – Premium Global Income Split Fund (the “Fund”) is pleased to announce it has established an at-the-market equity program (“ATM Program”) that allows the Fund to issue preferred shares and class A shares to the public from time to time, at the Fund’s discretion. The program replaces the prior program that was established in December 2024 that has terminated. Any preferred shares or class A shares sold under the ATM Program will be sold through the Toronto Stock Exchange (the “TSX”) or any other marketplace in Canada on which the class A shares and preferred shares are listed, quoted or otherwise traded at the prevailing market price at the time of sale. Sales of class A shares and preferred shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated September 21, 2026 (the “Equity Distribution Agreement”) with National Bank Financial Inc. (the “Lead Agent”) and CIBC World Markets Inc. (together with the Lead Agent, the “Agents”).

Sales of class A shares and preferred shares will be made by way of “at-the-market distributions” as defined in National Instrument 44-102 Shelf Distributions on the TSX or on any marketplace for the class A shares and preferred shares in Canada. Since the class A shares and preferred shares will be distributed at the prevailing market prices at the time of the sale, prices may vary among purchasers during the period of distribution. The ATM Program is being offered pursuant to a prospectus supplement dated September 21, 2026, to the Fund’s short form base shelf prospectus dated August 21, 2026. The maximum gross proceeds from the issuance of the shares will be $70,000,000. Copies of the prospectus supplement and the short form base shelf prospectus may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the Agents and are available on SEDAR+ at www.sedarplus.com.

The volume and timing of distributions under the ATM Program, if any, will be determined at the Fund’s sole discretion. The new program will be effective until September 20, 2028, unless terminated prior to such date in accordance with the terms of the Equity Distribution Agreement. The Fund intends to use the proceeds from the ATM Program in accordance with the investment objectives and investment strategies of the Fund, subject to the investment restrictions of the Fund.

The Fund invests in a diversified portfolio of primarily large capitalization global equity securities actively selected by its manager and investment manager, Mulvihill Capital Management Inc. (“Mulvihill”). To enhance the income generated by the Fund’s portfolio and to reduce volatility, the Fund employs an active covered call writing strategy and may write cash covered put options in respect of securities in which it is permitted to invest. The Fund may also invest up to 100% of its net assets in other public investment funds (including investment funds managed by Mulvihill). In addition, the Fund is exposed to securities traded in foreign currencies and may, at Mulvihill’s discretion, enter into currency hedging transactions to reduce the effects of changes in the value of foreign currencies relative to the value of the Canadian dollar.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com

John Germain, Senior Vice-President & CFO	Mulvihill Capital Management Inc. 25 King Street West Suite 2110 Toronto, Ontario, M5L 1A1

A short form base shelf prospectus and prospectus supplement containing important detailed information about the securities being offered has been filed with securities commissions or similar authorities in each of the provinces of Canada. Copies of the short form base shelf prospectus may be obtained from the Agents. Investors should read the short form base shelf prospectus and the prospectus supplement before making an investment decision.

You will usually pay brokerage fees to your dealer if you purchase or sell shares of the investment fund on the TSX. If shares of the Fund are purchased or sold on the TSX, investors may pay more than the current net asset value when buying shares of the investment fund and may receive less than the current net asset value when selling them.

There are ongoing fees and expenses associated with owning shares of an investment fund. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the investment fund in these documents. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful.